Clinical Trial Update: Two Fraction Prostate SBRT With DIL SIB [Phase 1]

View source ↗

Summary

A Phase 1 trial from NYU Langone Health is testing two-fraction prostate SBRT with a dominant intraprostatic lesion (DIL) simultaneous integrated boost (SIB) fo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: NYU Langone Health | Conditions: Prostate Cancer | Phase 1 | Status: RECRUITING